首页 | 本学科首页   官方微博 | 高级检索  
     


Brief Report: Homozygous IL37 mutation associated with infantile inflammatory bowel disease
Authors:Zinan Z. Zhang  Yu Zhang  Tingyan He  Colin L. Sweeney  Safa Baris  Elif Karakoc-Aydiner  Yikun Yao  Deniz Ertem  Helen F. Matthews  Claudia Gonzaga-Jauregui  Harry L. Malech  Helen C. Su  Ahmet Ozen  Kenneth G. C. Smith  Michael J. Lenardo
Affiliation:aNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, 20892;bCambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge CB2 0AW, United Kingdom;cSchool of Medicine, Marmara University, 34722 Istanbul, Turkey;dRegeneron Genetics Center, Tarrytown, NY, 10591
Abstract:
Interleukin (IL)-37, an antiinflammatory IL-1 family cytokine, is a key suppressor of innate immunity. IL-37 signaling requires the heterodimeric IL-18R1 and IL-1R8 receptor, which is abundantly expressed in the gastrointestinal tract. Here we report a 4-mo-old male from a consanguineous family with a homozygous loss-of-function IL37 mutation. The patient presented with persistent diarrhea and was found to have infantile inflammatory bowel disease (I-IBD). Patient cells showed increased intracellular IL-37 expression and increased proinflammatory cytokine production. In cell lines, mutant IL-37 was not stably expressed or properly secreted and was thus unable to functionally suppress proinflammatory cytokine expression. Furthermore, induced pluripotent stem cell–derived macrophages from the patient revealed an activated macrophage phenotype, which is more prone to lipopolysaccharide and IL-1β stimulation, resulting in hyperinflammatory tumor necrosis factor production. Insights from this patient will not only shed light on monogenic contributions of I-IBD but may also reveal the significance of the IL-18 and IL-37 axis in colonic homeostasis.
Keywords:immunodeficiency   inflammatory bowel disease   IBD   IL37   VEO-IBD
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号